Telos Capital Management Inc. Has $3.23 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Telos Capital Management Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,541 shares of the company’s stock after selling 160 shares during the quarter. Telos Capital Management Inc.’s holdings in Eli Lilly and Company were worth $3,230,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Fairfield Bush & CO. acquired a new stake in Eli Lilly and Company in the first quarter worth about $107,000. Roundview Capital LLC increased its position in Eli Lilly and Company by 2.6% in the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after purchasing an additional 53 shares during the period. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company in the first quarter worth about $210,000. NewEdge Advisors LLC increased its position in Eli Lilly and Company by 9.9% in the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after purchasing an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter worth about $561,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 0.7 %

Shares of NYSE LLY traded up $5.22 during trading hours on Wednesday, hitting $751.96. The company had a trading volume of 2,342,448 shares, compared to its average volume of 3,075,579. The stock has a market capitalization of $714.48 billion, a P/E ratio of 128.75, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The firm’s 50 day moving average is $763.51 and its 200-day moving average is $657.01.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 EPS. On average, analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.